Lisanne M. Geers, Taichi Ochi, Natalya M. Vyalova, Innokentiy S. Losenkov, Diana Z. Paderina, Ivan V. Pozhidaev, German G. Simutkin, Nikolay A. Bokhan, Bob Wilffert, Daniël J. Touw, Anton J.M. Loonen, Svetlana A. Ivanova
{"title":"8种ABCB1多态性对俄罗斯中重度抑郁症患者无治疗前瞻性队列抗抑郁反应的影响:一项自然设计的探索性精神药理学研究","authors":"Lisanne M. Geers, Taichi Ochi, Natalya M. Vyalova, Innokentiy S. Losenkov, Diana Z. Paderina, Ivan V. Pozhidaev, German G. Simutkin, Nikolay A. Bokhan, Bob Wilffert, Daniël J. Touw, Anton J.M. Loonen, Svetlana A. Ivanova","doi":"10.1002/hup.2826","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Many antidepressants are substrates of P-glycoprotein, an efflux transporter in the blood-brain-barrier encoded by the <i>ABCB1</i> gene. Genetic variations might influence the transport rate of antidepressants and hence their pharmacological effects. This study investigates the influence of eight polymorphisms in the <i>ABCB1</i> gene on antidepressant treatment response.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>152 patients were included from psychiatric departments of the Mental Health Research Institute in Tomsk. The difference in Hamilton-Depression-Rating-Scale (HAMD-17)-scores between baseline and week two, week two and four, and baseline and week four was used to estimate timing of improvement of depression. Associations between the <i>ABCB1</i> gene-polymorphisms and reduction in HAMD-17 score were assessed using independent <i>t</i>-test and multiple linear regression.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Tricyclic antidepressants were associated with a higher reduction of HAMD-17 score when compared to SSRIs. The SNP rs2235040 A-allele had a significant positive influence on the ΔHAMD-17<sub>(0→2W)</sub> score but a significant negative influence on the ΔHAMD-17<sub>(2→4W)</sub> score. The rs4148739 G-allele had a significant negative influence on the ΔHAMD-17<sub>(0→2W)</sub> score but a significant positive influence on the ΔHAMD-17<sub>(2→4W)</sub> score. The SNP rs2235015 T-allele is significant negatively related to the ΔHAMD-17<sub>(2→4W)</sub> score.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>ABCB1 Genetic variations appear to affect speed but not magnitude of antidepressant drug response.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"37 3","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/a4/HUP-37-0.PMC9285790.pdf","citationCount":"3","resultStr":"{\"title\":\"Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design\",\"authors\":\"Lisanne M. Geers, Taichi Ochi, Natalya M. Vyalova, Innokentiy S. Losenkov, Diana Z. Paderina, Ivan V. Pozhidaev, German G. Simutkin, Nikolay A. Bokhan, Bob Wilffert, Daniël J. Touw, Anton J.M. Loonen, Svetlana A. Ivanova\",\"doi\":\"10.1002/hup.2826\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Many antidepressants are substrates of P-glycoprotein, an efflux transporter in the blood-brain-barrier encoded by the <i>ABCB1</i> gene. Genetic variations might influence the transport rate of antidepressants and hence their pharmacological effects. This study investigates the influence of eight polymorphisms in the <i>ABCB1</i> gene on antidepressant treatment response.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Method</h3>\\n \\n <p>152 patients were included from psychiatric departments of the Mental Health Research Institute in Tomsk. The difference in Hamilton-Depression-Rating-Scale (HAMD-17)-scores between baseline and week two, week two and four, and baseline and week four was used to estimate timing of improvement of depression. Associations between the <i>ABCB1</i> gene-polymorphisms and reduction in HAMD-17 score were assessed using independent <i>t</i>-test and multiple linear regression.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Tricyclic antidepressants were associated with a higher reduction of HAMD-17 score when compared to SSRIs. The SNP rs2235040 A-allele had a significant positive influence on the ΔHAMD-17<sub>(0→2W)</sub> score but a significant negative influence on the ΔHAMD-17<sub>(2→4W)</sub> score. The rs4148739 G-allele had a significant negative influence on the ΔHAMD-17<sub>(0→2W)</sub> score but a significant positive influence on the ΔHAMD-17<sub>(2→4W)</sub> score. The SNP rs2235015 T-allele is significant negatively related to the ΔHAMD-17<sub>(2→4W)</sub> score.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>ABCB1 Genetic variations appear to affect speed but not magnitude of antidepressant drug response.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13030,\"journal\":{\"name\":\"Human Psychopharmacology: Clinical and Experimental\",\"volume\":\"37 3\",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2021-11-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/a4/HUP-37-0.PMC9285790.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Psychopharmacology: Clinical and Experimental\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hup.2826\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2826","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
Background
Many antidepressants are substrates of P-glycoprotein, an efflux transporter in the blood-brain-barrier encoded by the ABCB1 gene. Genetic variations might influence the transport rate of antidepressants and hence their pharmacological effects. This study investigates the influence of eight polymorphisms in the ABCB1 gene on antidepressant treatment response.
Method
152 patients were included from psychiatric departments of the Mental Health Research Institute in Tomsk. The difference in Hamilton-Depression-Rating-Scale (HAMD-17)-scores between baseline and week two, week two and four, and baseline and week four was used to estimate timing of improvement of depression. Associations between the ABCB1 gene-polymorphisms and reduction in HAMD-17 score were assessed using independent t-test and multiple linear regression.
Results
Tricyclic antidepressants were associated with a higher reduction of HAMD-17 score when compared to SSRIs. The SNP rs2235040 A-allele had a significant positive influence on the ΔHAMD-17(0→2W) score but a significant negative influence on the ΔHAMD-17(2→4W) score. The rs4148739 G-allele had a significant negative influence on the ΔHAMD-17(0→2W) score but a significant positive influence on the ΔHAMD-17(2→4W) score. The SNP rs2235015 T-allele is significant negatively related to the ΔHAMD-17(2→4W) score.
Conclusion
ABCB1 Genetic variations appear to affect speed but not magnitude of antidepressant drug response.
期刊介绍：
Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal:
-All aspects of clinical psychopharmacology-
Efficacy and safety studies of novel and standard psychotropic drugs-
Studies of the adverse effects of psychotropic drugs-
Effects of psychotropic drugs on normal physiological processes-
Geriatric and paediatric psychopharmacology-
Ethical and psychosocial aspects of drug use and misuse-
Psychopharmacological aspects of sleep and chronobiology-
Neuroimaging and psychoactive drugs-
Phytopharmacology and psychoactive substances-
Drug treatment of neurological disorders-
Mechanisms of action of psychotropic drugs-
Ethnopsychopharmacology-
Pharmacogenetic aspects of mental illness and drug response-
Psychometrics: psychopharmacological methods and experimental design
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
